Aspirin in cardiology - Benefits and risks

International Journal of Clinical Practice

Volumn 63, Issue 3, 2009, Pages 468-477

  Bjorklund L ^a   Wallander, M A ^b,c   Johansson, S ^a,b   Lesen E ^a,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; MISOPROSTOL; OMEPRAZOLE; PLACEBO; WARFARIN;

BLEEDING; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; EMBASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEMORRHAGIC STROKE; HUMAN; INCIDENCE; MEDLINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; SCISEARCH; STOMACH INJURY; STROKE; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; ASPIRIN; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS;

EID: 59349115915     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01908.x     Document Type: Review

References (91)

1. World Health Organization. The World Health Report 2004 - Changing History. Geneva : World Health Organization, 2004. http://www.who.int/whr/2004/ en/index.html (accessed March 2007).
2. Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004 80 : 155 64.
3. Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. J Intern Med 2002 251 : 193 206.
4. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992 25 : 249 65.
5. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007 23 : 163 73.
6. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001 107 : 1491 5.
7. Forster W, Parratt JR. The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low? Cardiovasc Drugs Ther 1997 10 : 727 34.
8. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998 38 : 97 120.
9. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004 18 : 790 804.
10. McCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Res Clin Gastroenterol 2001 15 : 755 73.
11. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997 49 : 15 9.
12. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004 351 : 1709 11.
13. Slepian IK, Mathews KP, McLean JA. Aspirin-sensitive asthma. Chest 1985 87 : 386 91.
14. Szczeklik A. Mechanism of aspirin-induced asthma. Allergy 1997 52 : 613 9.
15. Hung J. Aspirin for cardiovascular disease prevention. Med J Aust 2003 179 : 147 52.
16. Baigent C, Sudlow C, Collins R et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 : 71 86.
17. Altman R, Carreras L, Diaz R et al. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 308 : 81 106.
18. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005 352 : 1293 304.
19. Awtry EH, Loscalzo J. Aspirin. Circulation 2000 101 : 1206 18.
20. Manolis AS, Tzeis S, Andrikopoulos G et al. Aspirin and clopidogrel: a sweeping combination in cardiology. Curr Med Chem Cardiovasc Hematol Agents 2005 3 : 203 19.
21. Hart RG, Halperin JL, McBride R et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000 57 : 326 32.
22. Ezekowitz JA, Straus SE, Majumdar SR et al. Stroke: strategies for primary prevention. Am Fam Physician 2003 68 : 2379 86.
23. Nelson MR, Liew D, Bertram M et al. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥ 70. BMJ 2005 330 : 1306.
24. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and non-aspirin non-steroidal anti-inflammatory drugs. Am J Epidemiol 2004 159 : 23 31.
25. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001 1 : 1.
26. Laheij RJ, Jansen JB, Verbeek AL et al. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther 2001 15 : 1055 9.
27. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002 288 : 1388 95.
28. Mehta P. Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002 17 : 552 8.
29. Grundy SM, Pasternak R, Greenland P et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999 100 : 1481 92.
30. Hayden M, Pignone M, Phillips C et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 136 : 161 72.
31. Weil J, Langman MJ, Wainwright P et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000 46 : 27 31.
32. Ng TM, Fock KM, Khor JL et al. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. Aliment Pharmacol Ther 2000 14 : 203 9.
33. Neutel CI, Appel WC. The effect of alcohol abuse on the risk of NSAID-related gastrointestinal events. Ann Epidemiol 2000 10 : 246 50.
34. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 343 : 769 72.
35. Sorensen HT, Mellemkjaer L, Blot WJ et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000 95 : 2218 24.
36. Lanas A, Garcia-Rodriguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006 55 : 1731 8.
37. Buresly K, Eisenberg MJ, Zhang X et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005 165 : 784 9.
38. Ng W, Wong WM, Chen WH et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol 2006 12 : 2923 7.
39. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995 310 : 827 30.
40. Serebruany VL, Steinhubl SR, Berger PB et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005 95 : 1218 22.
41. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999 117 : 17 25.
42. Sung J, Lau J, Ching J et al. Can aspirin be reintroduced with proton pump inhibitor infusion after endoscopic hemostasis? A double blinded randomized controlled trial. Gastroenterology 2006 130 (4 Suppl. 2 A44.
43. Slattery J, Warlow CP, Shorrock CJ et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995 37 : 509 11.
44. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993 105 : 1078 88.
45. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000 160 : 2093 9.
46. Lewis SC, Langman MJ, Laporte JR et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002 54 : 320 6.
47. Yeomans ND, Lanas A, Labenz J et al. Prevention of low-dose aspirin-associated gastroduodenal ulcers and upper gastrointestinal symptoms in patients receiving esomeprazole 20 mg per day. Gastroenterology 2006 130 (4 Suppl. 2 81 (A561).
48. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002 346 : 2033 8.
49. Lanas A, Ferrandez A. Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opin Drug Saf 2002 1 : 245 52.
50. Donnelly MT, Goddard AF, Filipowicz B et al. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000 14 : 529 34.
51. Yilmaz S, Bayan K, Dursun M et al. Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study. Dig Dis Sci 2007 52 : 110 8.
52. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
53. Jneid H, Bhatt DL, Corti R et al. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med 2003 163 : 1145 53.
54. Bertrand ME, Simoons ML, Fox KA et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002 23 : 1809 40.
55. Peters RJ, Mehta SR, Fox KA et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003 108 : 1682 7.
56. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004 364 : 331 7.
57. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 1999 13 : 1109 14.
58. Hawthorne AB, Mahida YR, Cole AT et al. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991 32 : 77 83.
59. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996 348 : 1413 6.
60. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003 10 : S1 10.
61. Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003 107 : 149 58.
62. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004 110 : 588 636.
63. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002 106 : 1893 900.
64. Pearson TA, Blair SN, Daniels SR et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002 106 : 388 91.
65. Berg AO, Allan JD, Frame PS et al. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002 136 : 157 60.
66. Saseen JJ. ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events. Am J Health Syst Pharm 2005 62 : 1398 405.
67. Martinez M, Agusti A, Arnau JM et al. Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. Eur J Clin Pharmacol 1998 54 : 203 8.
68. Burwen DR, Galusha DH, Lewis JM et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003 163 : 1430 9.
69. Rogers WJ, Canto JG, Lambrew CT et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000 36 : 2056 63.
70. Herlitz J, McGovern P, Dellborg M et al. Comparison of treatment and outcomes for patients with acute myocardial infarction in Minneapolis/St. Paul, Minnesota, and Goteborg, Sweden. Am Heart J 2003 146 : 1023 9.
71. O'Connor GT, Quinton HB, Traven ND et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 1999 281 : 627 33.
72. Murray S. Does sex affect how patients respond to ASA? CMAJ 2006 174 : 773.
73. Berger JS, Roncaglioni MC, Avanzini F et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006 295 : 306 13.
74. Stack WA, Atherton JC, Hawkey GM et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002 16 : 497 506.
75. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000 321 : 1183 7.
76. van Gijn J, Algra A, Kappelle J et al. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 1991 325 : 1261 6.
77. Tijssen JG. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology 1998 51 (3 Suppl. 3 S15 6.
78. Dudley NJ, Bowling A, Bond M et al. Age- and sex-related bias in the management of heart disease in a district general hospital. Age Ageing 2002 31 : 37 42.
79. Spencer F, Scleparis G, Goldberg RJ et al. Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 2001 142 : 594 603.
80. Krumholz HM, Radford MJ, Ellerbeck EF et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996 124 : 292 8.
81. Gage BF, Boechler M, Doggette AL et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000 31 : 822 7.
82. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000 101 : 1097 101.
83. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003 55 : 604 8.
84. Carroll K, Majeed A, Firth C et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 2003 25 : 29 35.
85. Perers E, Caidahl K, Herlitz J et al. Treatment and short-term outcome in women and men with acute coronary syndromes. Int J Cardiol 2005 103 : 120 7.
86. Avelar E, Woods SE, Doerzbacher M et al. The influence of multiple variables on the prevalence of aspirin prescribing in patients with known coronary artery disease. Heartdrug 2003 3 : 82 6.
87. Hippisley-Cox J, Pringle M, Crown N et al. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001 322 : 832.
88. Hanratty B, Lawlor DA, Robinson MB et al. Sex differences in risk factors, treatment and mortality after acute myocardial infarction: an observational study. J Epidemiol Community Health 2000 54 : 912 6.
89. Ayanian JZ, Guadagnoli E, McNeil BJ et al. Treatment and outcomes of acute myocardial infarction among patients of cardiologists and generalist physicians. Arch Intern Med 1997 157 : 2570 6.
90. Chan A, Ng FH, Chang CM et al. Prevalence and prediction of gastrointestinal events in patients receiving a combination of aspirin plus clopidogrel. Gastroenterology 2007 132 (Suppl. 1 916.
91. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005 352 : 238 44.